sanofi-aventis acquires TargeGen for $560 million
Clients sanofi-aventis S.A.
Jones Day advised sanofi-aventis S.A. in reaching a $560 million merger agreement with TargeGen Inc., a privately held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. In addition to M&A representation, Jones Day provided tax, benefits and IP advice regarding this transaction.